Drug intelligence / Profile preview

hectinib

Development stage: Unknown
Lead developer: Calgent Biotechnology
Modality: Small Molecules
Administration: Oral

Overview

Hectinib is an orally bioavailable small molecule developed by Calgent Biotechnology that targets the HECT (Homologous to the E6-AP Carboxyl Terminus) family of E3 ubiquitin ligases. By modulating or inhibiting the activity of these ligases, Hectinib aims to disrupt the protein degradation pathways that multiple myeloma cells rely on for survival and proliferation. The drug has received Orphan Drug Designation from the FDA for the treatment of multiple myeloma and is currently undergoing clinical evaluation.

Targets

E3 ligase (E3 ubiquitin ligases)

Beyond the preview

Go deeper on hectinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hectinib.

Explore the full profile